XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.20.2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS | 12 Months Ended
--- | ---
Apr. 30, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] |
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS | PHARMACYTE BIOTECH, INC. SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS Years Ended April 30, 2020 and 2019
Description |  | Balance at Beginning of Year |  |  | Additions Charged to Costs and Expenses |  |  | Charged to Other Accounts |  |  | Deductions |  |  | Balance at End of Year |
Reserve Deducted in the Balance Sheets from the Asset to which it applies: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allowance for Deferred Tax Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Year ended April 30, 2020 |  | $ | 14,187,771 |  |  |  | – |  |  |  | 1,341,187 |  |  |  | – |  |  |  | 15,528,958 |
Year ended April 30, 2019 |  | $ | 13,235,601 |  |  |  | – |  |  |  | 952,170 |  |  |  | – |  |  |  | 14,187,771 |

X
- Definition The entire disclosure for valuation and qualifying accounts and reserves. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 09 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690 + Details
Name: | srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | srt_ValuationAndQualifyingAccountsAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration